One day after announcing a drop in quarterly sales and profits, Danish drugmaker Lundbeck said it will pick up Chelsea Therapeutics for cash and contingent value rights in a deal worth up to $658 million.
written on 08.05.2014
One day after announcing a drop in quarterly sales and profits, Danish drugmaker Lundbeck said it will pick up Chelsea Therapeutics for cash and contingent value rights in a deal worth up to $658 million.
See our Cookie Privacy Policy Here